Key Highlights: Implications: Nucelion and VeGen Bio’s partnership could strengthen India’s domestic CAR-T manufacturing ecosystem by combining dual-target therapy development with G...
Key Highlights: Implications: Qfitlia’s Indian authorization strengthens Sanofi’s haemophilia portfolio with an antithrombin-lowering approach that offers protection for haemophilia A and ...
Key Highlights: Implications: Zytorvi’s approval strengthens Dr. Reddy’s position in India’s esophageal cancer market by expanding access to first-line PD-1 immunotherapy without PD-...
Key Highlights: Implications: Mankind Pharma’s €48 million investment for a 70% stake in ACTx signals a strategic shift toward high-value oncology and next-generation CAR-T therapies. ACTx...
Key Highlights: Implications: Peptris Technologies’ ₹86 crore RDI support highlights India’s push to translate AI-driven drug discovery into development-ready candidates. Advancing four pr...
Key Highlights: Implications: NuSynth’s ₹36.5 crore seed round reflects growing investor interest in AI-enabled chemical manufacturing, where data-driven experimentation can improve proces...
Key Highlights: Implications: AstraZeneca’s positive SEC recommendation could accelerate Etcamah’s entry into India’s emerging ESR1-mutated breast cancer segment without a local Phase III ...
Key Highlights: Implications: Granules India’s ₹2,000 crore investment signals an aggressive shift toward higher-margin, complex generics, oncology and peptide CDMO, reducing reliance on commodi...
Key Highlights: Implications: Lupin’s launch of Formoflo-G strengthens its respiratory leadership by offering a differentiated triple-combination MDI for COPD. The single-inhaler approach ...
Key Highlights: Implications: Akums’ CDSCO/DCGI approval to manufacture colchicine 0.5 mg for cardiovascular risk reduction is a “first‑time‑in‑India” regulatory milestone that lets India’...